Pharmacogenetics driving personalized medicine: Analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations by Cocca, Massimiliano et al.
Cocca et al. J Transl Med  (2016) 14:22 
DOI 10.1186/s12967-016-0778-z
RESEARCH
Pharmacogenetics driving personalized 
medicine: analysis of genetic polymorphisms 
related to breast cancer medications in Italian 
isolated populations
Massimiliano Cocca1†, Davide Bedognetti2†, Martina La Bianca3, Paolo Gasparini1,4 and Giorgia Girotto1,4*
Abstract 
Background: Breast cancer is the most common cancer in women characterized by a high variable clinical outcome 
among individuals treated with equivalent regimens and novel targeted therapies. In this study, we performed a 
population based approach intersecting high-throughput genotype data from Friuli Venezia Giulia (FVG) isolated pop-
ulations with publically available pharmacogenomics information to estimate the frequency of genotypes correlated 
with responsiveness to breast cancer treatment thus improving the clinical management of this disease in an efficient 
and cost effective way.
Methods: A list of 80 variants reported to be related to the efficacy or toxicity of breast cancer drugs was obtained 
from PharmGKB database. Fourty-one were present in FVG, 1000G European (EUR) and ExAC (Non Finnish European) 
databases. Their frequency was extracted using PLINK software and the differences tested by Fisher’s exact test.
Results: Statistical analyses revealed that 13 out of the 41 (32 %) variants were significantly different in frequency in 
our sample as compared to the EUR/ExAC cohorts. For nine variants the available level of evidence (LOE) included 
polymorphisms related to cyclophosphamide, tamoxifen, doxorubicin, fluorpyrimidine and paclitaxel. In particular, 
for trastuzumab two variants were detected: (1) rs1801274-G within FCGR2A and associated with decreased efficacy 
(LOE 2B); (2) rs1136201-G located within ERBB2 and associated with increased toxicity (LOE 3). Both these two variants 
were underrepresented in the FVG population compared to EUR/ExAC population thus suggesting a high therapeutic 
index of this drug in our population. Moreover, as regards fluoropyrimidines, the frequency of two polymorphisms 
within the DPYD gene associated with drug toxicity (e.g., rs2297595-C allele and rs3918290-T allele, LOE 2A and 1, 
respectively) was extremely low in FVG population thus suggesting that a larger number of FVG patients could ben-
efit from full dosage of fluoropyrimidine therapy.
Conclusions: All these findings increase the overall knowledge on the prevalence of specific variants related with 
breast cancer treatment responsiveness in FVG population and highlight the importance of assessing gene polymor-
phisms related with cancer medications in isolated communities.
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Background
The development of refined technologies for genetic 
analysis (e.g., next-generation sequencing, genotyping, 
etc.), paired with a continuous optimization of computa-
tional and bioinformatic tools, has recently unveiled the 
scope of human genetic variations. These high-through-
put approaches led to the discovery of novel disease-
associated variants, germline mutations responsible 
for rare genetic diseases, and, as far as the cancer field 
is concerned, to the identification of somatic mutations 
predictive of treatment responsiveness [1]. The charac-
terization of patient-specific genetic make up is critical 
for the development of personalized interventions. A 
medication that is proven efficacious in many patients, 
often fails to work in others. Furthermore, even if a cer-
tain drug is active, it still may cause serious side effects 
[2]. Pharmacogenomics addresses this issue by seeking to 
identify genetic contributors to human variation in drug 
efficacy and toxicity with the hope of developing person-
alized treatments.
Breast cancer is the most common cancer in women 
worldwide. An early detection combined with an appro-
priate treatment has proved to be effective in reducing 
risk of death and relapse [3–5]. Nevertheless, in the adju-
vant setting, only few patients will actually benefit from 
the treatment. Similarly, a wide degree of variation in 
treatment sensitivity is observed in metastatic setting.
There is a tremendous effort to identify factors associ-
ated with treatment responsiveness [6–8]. Although most 
of the studies have been focusing on tumor characteris-
tics, it is clear that host’s genetic make up can influence 
treatment tolerability and outcome.
The effect of several major antineoplastic agents is 
influenced by genetic polymorphisms of different nature 
ranging from the target itself (e.g., transtuzumab and 
HER2 [9] to metabolic pathways (e.g., capecitabine 
and DPYD) [10]. In breast cancer, as for other diseases, 
there is high degree of heterogeneity in term of clinical 
outcome among individuals treated with equivalent reg-
imens such as hormonal agents (e.g., tamoxifen), cyto-
toxic agents (e.g., capecitabine), and targeted therapies 
[11].
In view of this heterogeneity, an increased awareness 
of the distribution of risk variants within a specific popu-
lation (or community) is critical to plan tailored health-
care interventions [12]. At the best of our knowledge, 
many studies described drug response related to the 
variations in the general population but none of them 
have so far analyzed the prevalence of defined risk alleles 
(i.e., variants associated with treatment toxicity or treat-
ment failure) in isolated communities such as those ones 
described below. In fact, the detection of an unusual high 
rate of one or more risk variants in a defined community 
could prompt the local authority to implement ad-hoc 
screening strategies, which wouldn’t be otherwise cost-
effective in the general population. In addition, physi-
cians can use this information to better sharpen the 
risk–benefit ratio of a specific intervention in every-day 
clinical practice.
Here, we developed an analytic pipeline that intersects 
high-throughput genotype data with publically available 
pharmacogenomics information. Through this approach, 
we described the frequency of genetic markers correlated 
with responsiveness to breast cancer treatment in the 
Friuli Venezia Giulia (FVG) population with the aim of 
improving clinical management of this disease in a cost-
effective way. FVG is an autonomous region located in 
North Eastern Italy at the border with Austria and Slo-
venia constituted by 1.2 million of inhabitants. Thanks to 
this autonomy and to the effective clinical data exchange 
between different health service providers, FGV has 
developed a regional health care network (RHCN) ensur-
ing continuity of care and improved health services for 
citizens of this region. This exchange is facilitated by an 
information technology (IT) infrastructure that allows a 
continuous and up-to-date secure exchange of medical 
data and records. As of 2008, medical data from hospi-
tals, primary care physicians, and pharmacies (digital 
prescription records) are all accessible through this IT 
infrastructure in a strictly regulated manner.
Moreover, in 2009, two population based research 
pilot projects have been started. One is the FVG genetic 
park, focused in studying six isolated communities of 
this region (Erto-Casso, Clauzetto, Resia, Sauris, San 
Martino del Carso, and Illegio) for an overall number 
of approximately 2500 inhabitants [13]. The second one 
is the MoMa, which aims at investigating dismetabolic 
syndromes in another large community of the region 
(Montereale/Maniago, approx. 15,000 inhabitants). Both 
volunteer-based projects, representing approximately 2 % 
of the adult population living in the FVG autonomous 
region, have established a biobank which stores biologi-
cal samples and a huge collection of clinical data. Taken 
together, the existence of all the elements mentioned 
above sets FVG Region in a globally unique position for 
the implementation of genomic medicine.
Methods
Sample collection, DNA sampling and genotyping
One thousand five hundred ninety samples from the 
FGV genetic park (six isolated villages, see Fig. 1) project 
were used for our genomic analyses (Additional file  1: 
Table S1) [13]. Information from a standardized health 
examination with collection of a series of deep pheno-
types (neurological, psychiatric, audiological, ophtal-
mological, cardiovascular, etc.) and a questionnaire on 
Page 3 of 12Cocca et al. J Transl Med  (2016) 14:22 
health-related topics, such as lifestyle and diet were col-
lected from all participants. The exact number of par-
ticipants divided by village, together with information 
about sex and mean age are reported in Additional file 1: 
Table S1. DNA from blood samples was extracted using 
standard protocols. All the 1590 subjects were genotyped 
using the HumanExome BeadChip. In addition, a subset 
of 1259 individuals has been genotyped using the Illu-
mina HumanCNV370-Quadv3_C (300  K), and another 
subset (N = 331) with the Illumina HumanOmniExpress-
12v1-Multi_C chip (700 K) (see Fig. 2). Genotype quality 
control and data cleaning were performed as previously 
described [13]. Considering the different genotyping 
platforms, the number of samples available for the anal-
ysis of each variant ranged from 331 to 1590 (the vast 
majority of cases) as described in Table 1. All participants 
have signed a broad informed consent form (a 5 years fol-
low-up is now in progress), which allows the continuous 
updating of epidemiological data through periodical link-
ing to National electronic databases and registries. The 
research was conducted according to the ethical stand-
ards defined by the Helsinki declaration. The study was 
approved by the Institutional Review Board of IRCCS 
Burlo Garofolo PROT CE/v-78.
Comparison between populations
All variants reported to be related to the efficacy or toxic-
ity of breast cancer drugs were extracted from PharmGKB 
database (https://www.pharmgkb.org/ [14]), obtaining 
a set of 80 single nucleotide polymorphisms (SNPs), all 
located on autosomal chromosomes. The overlap between 
these data and our population’s genotypes resulted in two 
catalogs of 37 and 23 loci (respectively from joint dataset 
and HumanExome chip) for a unique list of 41 variants. 
Among these 41 variants we extracted frequency infor-
mation in the general European cohort from 379 people 
of the 1000G Project data (EUR population) [15], 33,368 
people (Non Finnish European individuals) from the 
ExAC database and [16] 1590 individuals from the FVG 
population using PLINK software [17].
For each variant, differences in allele frequencies 
between the three populations were tested by Fisher’s 
exact test. Due to the high number of people included in 
ExAC database compared to 1000G data, the estimation 
of frequencies is more precise thus leading to a higher 
significance p value. Because of the explorative nature of 
our analysis, no multiple testing corrections were per-
formed, and a p value ≤0.05 was considered statistically 
significant.
Aggregated analysis of risk variants
In order to estimate the overall genotype’s risk for thera-
peutical agents, six main classes of drugs were defined 
as follows: (1) fluoropyrimidines, (2) alkylating agents, 
(3) taxanes, (4) antracyclines/tumor antibiotics, (5) anti-
estrogens, and (6) monoclonal antibodies. For each class 
of drugs, all the variants associated with breast cancer 
medications and having a different frequency between 
the FGV and the EUR/ExAC populations, were pooled 
and the proportion of the “at risk” genotypes in our pop-
ulation was defined.
Results
A cohort of 1590 individuals from six different isolated 
villages located in FVG region was used as the base for 
the study (Fig. 1 and Additional file 1: Table S1). Out of 
80 variants and 58 genes related to breast cancer medica-
tions according to the PharmGKB database, 41 variants 
in 32 genes were present in our genotyping platforms 
for the six isolated populations (Additional file  2: Table 
S2 and Fig.  2). The frequencies of 13 out of 41 variants 
(i.e., 32 %) were different between FGV and EUR/ExAC 
cohorts (Table  1). When available, level of evidence 
(LOE) of the variant-drug combination, scoring from 
1 (annotation for which pharmacogenomics guidelines 
are implemented in clinical practice) to 4 (annotation 
based on a case report, non-significant study or in vitro, 
molecular or functional assay evidence only), is reported 
in Table  2. A more detailed description of these differ-
ences and the relative clinical impact is described in 
Fig. 1 Friuli Venezia Giulia villages. Geographic location of the six 
isolated villages in the Friuli Venezia Giulia region (North Eastern Italy) 
analyzed in this study. The overall number of recruited people is 1590
Page 4 of 12Cocca et al. J Transl Med  (2016) 14:22 
the following sections. We will first describe differences 
for those SNPs for which an association with activity 
or toxicity has been reported (LOE 1–4), see Table  2A. 
Then, we will discuss differences for the SNPs that were 
reported as “related” with breast cancer medications but 
for each the evidence supporting the association is lack-
ing (LOE not reported; Table  2B). Finally, we will pre-
sent the cumulative frequency of at risk genotype for the 
defined categories of drugs.
Genetic variants associated to breast neoplasm 
medications
By using our analytical pipeline, we found nine variants 
associated with drug toxicity or efficacy having a differ-
ent distribution between the FGV and the EUR/ExAC 
populations supported by a certain LOE (Table 2A). The 
level of association was reported as statistically signifi-
cant in at least one study for seven of them (LOE 1–3) 
and borderline significant for one of them (rs4244285; 
Fig. 2 Pipeline used for variants’ selection. Three steps were carried out: Step (1) 80 variants and 58 genes related to breast cancer medicationsa 
ccording to the PharmGKB database were considered. Step (2) Variants selected in the previous step were overlapped with data from the available 
genotyping platforms in the FVG cohort: 41 variants and 32 genes were used for further analysis. Step (3) Frequencies for the 41 variants selected in 
step 2 were compared between FVG and EUR cohorts, resulting in a set of 13 variants. Among them, for nine variants the association was supported 
by a certain LOE
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Table 1 Alleles frequencies among  FVG, 1000G and  ExAC (Non Finnish European population) data of  a selected list 
of SNPs reported as associated with specific drugs in the PharmGkB database
Snp id
(gene)
Drugs (reported as related 
by PharmGKB database)
Alleles Af_FVG Af_1000G_EUR Af_ExAC_NFE Samples p value
vs EUR
p value
vs ExAC
rs3918290
(DPYD)
Capecitabine T/C 0.0006325 0.01 0.0058 1581 2.062E−05 2.20E−04
rs1136201
(ERBB2)
Trastuzumab G/A 0.1692 0.25 0.2396 1581 3.562E−05 2.37E−13
rs2369049
(TCL1A)
Exemestane G/A 0.1111 0.17 NA 1580 1.411E−04 NA
rs4244285
(CYP2C19)
Doxorubicin, cyclophosphamide,  
tamoxifen
A/G 0.08485 0.15 0.1477 330 1.077E−03 7.27E−05
rs714368
(SLC22A16)
Doxorubicin, doxorubicinol C/T 0.2726 0.21 0.2218 1590 6.932E−03 1.73E−07
rs776746
(CYP3A5)
Tamoxifen T/C 0.08055 0.05 NA 1589 8.936E−03 NA
rs1801274
(FCGR2A)
Trastuzumab, doxorubicin, paclitaxel, 
cyclophosphamide
G/A 0.4195 0.5 0.4942 1590 1.457E−02 9.20E−07
rs4880
(SOD2)
Cyclophosphamide G/A 0.5452 0.46 0.5162 1581 1.877E−02 7.81E−02
rs1801159
(DPYD)
Capecitabine C/T 0.217 0.17 0.1978 1581 2.155E−02 3.36E−02
rs2072671
(CDA)
Capecitabine C/A 0.397 0.33 0.3427 1587 2.326E−02 1.79E−05
rs2297595
(DPYD)
Fluorouracil, capecitabine C/T 0.09077 0.12 0.1027 1581 3.256E−02 5.40E−02
rs1048943
(CYP1A1)
Docetaxel, capecitabine C/T 0.06839 0.04 0.0332 1581 2.374E−02 5.66E−18
rs6214
(IGF1)
Tamoxifen T/C 0.3518 0.41 NA 1589 4.746E−02 NA
rs1695
(GSTP1)
Docetaxel, epirubicin, fluorouracil,  
doxorubicin, cyclophosphamide
G/A 0.2761 0.32 0.3191 1590 8.264E−02 2.11E−04
rs12210538
(SLC22A16)
Doxorubicin, cyclophosphamide G/A 0.2125 0.25 0.2351 1581 8.411E−02 2.11E−02
rs9024
(CBR1, SETD4)
Doxorubicin, doxorubicinol A/G 0.1243 0.1 NA 1585 1.116E−01 NA
rs7349683
(EPHA5)
Paclitaxel T/C 0.4169 0.37 0.3588 1589 1.312E−01 8.26E−06
rs45589337
(DPYD)
Cyclophosphamide, fluorouracil,  
methotrexate
C/T 0.004744 0.01 0.0155 1581 1.504E−01 2.90E−06
rs10509373
(C10orf11)
Tamoxifen C/T 0.469 0.42 NA 1258 1.544E−01 NA
rs1056836
(CYP1B1)
Docetaxel, paclitaxel, taxanes G/C 0.5728 0.63 0.5675 1580 1.551E−01 7.69E−01
rs723685
(SLC22A16)
Doxorubicin, cyclophosphamide G/A 0.1069 0.09 0.0886 1590 2.396E−01 1.28E−03
rs1143684
(NQO2)
Doxorubicin, cyclophosphamide T/C 0.7434 0.8 0.787 1588 2.401E−01 4.18E−02
rs9561778
(ABCC4)
Doxorubicin, cyclophosphamide,  
fluorouracil
T/G 0.2085 0.18 NA 331 2.943E−01 NA
rs2032582
(ABCB1)
Anthracyclines and related substances, 
paclitaxel, doxorubicin,  
cyclophosphamide, taxanes
C/A 0.6091 0.57 0.5523 1581 3.374E−01 9.99E−04
rs8133052
(CBR3)
Doxorubicin A/G 0.4817 0.45 0.5904 1587 3.647E−01 5.46E−09
rs2290272
(SLC28A1)
Capecitabine A/G 0.3569 0.38 0.3466 1590 4.403E−01 4.20E−01
rs1128503
(ABCB1)
Doxorubicin G/A 0.5317 0.57 0.5726 331 4.631E−01 2.78E−01
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LOE 4). In one case (rs714368), two studies reported 
opposite results (LOE 4), as described below (Table 2A). 
The type and the position of these variants are reported 
in Table  2A. Eight of them are missense variants, while 
two of them are annotated as splicing variants. For the 
remaining three one is a synonymous variant, one is 
located in UTR3 site and one is located in an intergenic 
region. A more detailed description of each variant 
including data on in silico prediction is reported in the 
Additional file 3: Table S3. Considering the variants that 
affect the splicing, one is reported to be a spice donor 
(rs3918290) and the other one (rs776746) as a splice 
acceptor located in the UTR5. In this light, a change in 
these sites could have functional consequences.
Doxorubicine and cyclophosphamide are the backbone 
of the chemotherapeutic regimens used for the treat-
ment of breast cancer patients. Cyclophosphamide is a 
pro-drug that needs to be oxidized to exert its cytotoxic 
effect. This step is catalyzed by a number of cytochrome 
P450 enzymes, including CYPC219 [18]. The cellu-
lar uptake of doxorubicine is mediated by ABCB1 and 
SLC22A16 cationic transporters [19].
As regards CYP2C19, the rs4244285 variant has been 
reported to be associated with differential response to 
cyclophosphamide–doxorubicin adjuvant regimen. The 
frequency of the A allele in the EUR/ExAC cohorts and 
in the mixed population is 15  % while in our cohort is 
8 % (p = 1.1E−03) (Table 1). The GG genotype was the 
most frequent in FVG cohorts (with the highest number 
in Resia valley) (Table  2A). According to a single retro-
spective study [19], individuals bearing the AA genotype 
show a trend of an increased risk of poorer outcome if 
treated with cyclophosphamide–doxorubicin polychem-
otherapeutic regimen (LOE 4) although other studies are 
partially discordant [20].
As for SLC22A16 gene, the rs714368 polymorphism, 
which is related to doxorubicin response, has a frequency of 
35 % for the C allele in the Asian population; the frequency 
Table 1 continued
Snp id
(gene)
Drugs (reported as related 
by PharmGKB database)
Alleles Af_FVG Af_1000G_EUR Af_ExAC_NFE Samples p value
vs EUR
p value
vs ExAC
rs351855
(FGFR4)
Cyclophosphamide, fluorouracil,  
methotrexate
A/G 0.309 0.29 0.3029 1581 4.805E−01 6.06E−01
rs7136446
(IGF1)
tamoxifen T/C 0.6372 0.61 NA 1589 5.265E−01 NA
rs1801133
(CLCN6,MTHFR)
Cyclophosphamide, fluorouracil A/G 0.3674 0.35 0.345 1584 5.661E−01 7.67E−02
rs1045642
(ABCB1)
Idarubicin, taxanes, cyclophosphamide, 
fluorouracil, epirubicin, anthracyclines 
and related substances, doxorubicin, 
paclitaxel, cytarabine, tamoxifen
G/A 0.4894 0.47 0.4719 331 6.992E−01 6.17E−01
rs717620
(ABCC2)
Tamoxifen T/C 0.2009 0.21 0.1993 331 7.801E−01 9.71E−01
rs3740065
(ABCC2)
Tamoxifen G/A 0.1163 0.11 NA 331 8.022E−01 NA
rs1800566
(NQO1)
Fluorouracil, epirubicin doxorubicin, 
cyclophosphamide
A/G 0.2044 0.2 0.188 1590 8.642E−01 6.10E−02
rs4646
(CYP19A1)
Letrozole C/A 0.7221 0.71 0.7481 331 8.697E−01 5.78E−01
rs9322336
(ESR1)
Exemestane T/C 0.7825 0.77 NA 331 8.729E−01 NA
rs8060157
(ZNF423)
Tamoxifen, raloxifene G/A 0.5548 0.56 NA 1258 9.202E−01 NA
rs1056892
(CBR3)
Doxorubicin A/G 0.3566 0.36 0.3481 1590 9.352E−01 5.05E−01
rs10509681
(CYP2C8)
Paclitaxel C/T 0.1086 0.11 0.1132 1589 9.719E−01 4.89E−01
rs20572
(CBR1, SETD4)
Doxorubicin, doxorubicinol T/C 0.0997 0.1 0.1144 331 1.00 3.18E−01
Out of 41 variants selected for the analysis, thirteen of them (in italics) were found as significantly different in frequency in our sample as compared to the EUR cohort
Snp id variant name, Gene target gene, Drugs medication reported to be correlated with a variant/gene in PharmGkB database (https://www.pharmgkb.org/), Alleles 
variant alleles (tested allele in italics), Af_FVG allele frequency of the FVG population, Af_1000G_EUR allele frequency of 1000G European population, Af_ExAC_NFE 
allele frequency in ExAC Non Finnish European populations, Samples sample number, p value vs EUR p value from Fisher test versus EUR population from 1000G (total 
sample size 379), p value vs ExAC p-value from Fisher test versus ExAC populations (total sample size 33,368)
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Table 2 Genotype’s counts for the 13 variants described as related to breast cancer medications in Italian isolated popu-
lations
A) variants that show significant difference in frequency between FVG sample set and EUR/ExAC populations in terms of level of association with drug response
B) variants that don’t show a level of evidence for drug response
As in most case the association has been evaluated in the context of polychemotherapeutic regimens, the most likely drug related to the target polymorphism is 
reported in italic
Snp id (gene) variant name, gene name, Functional annotation functional annotation for the variant, Level of evidence based on the amount of evidence reported at 
https://www.pharmgkb.org/that supports the association, Druga medication reported to be correlated with a variant/gene after checking the literature thus filtering 
out the non-significative association reported in PharmGKB database, Minor minor allele, Major major allele, Genotype genotype’s count for FVG population
Most of the studies were conduced in the context of polychemitherapeutic regimens; in such studies the drugs most likely related to the targeted polymorphisms 
according to the available literature are highlighted in italics; Parameters reported by PharmaGKB database. efficacy poor outcome, toxicity significant side effects, Risk 
allele risk allele reported in literature.b for variant rs776746 data for this variant was not available in the ExAC database at the time of the analysis, Genotype genotype’s 
counts
Level 1A: annotation for a variant-drug combination in a CPIC or medical society-endorsed PGx guideline, or implemented at a PGRN site or in another major health 
system; Level 1B: annotation for a variant-drug combination where the preponderance of evidence shows an association. The association must be replicated in more 
than one cohort with significant p-values, and preferably will have a strong effect size; Level 2A: annotation for a variant-drug combination that qualifies for level 
2B where the variant is within a VIP (very important pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional 
significance is more likely; Level 2B: annotation for a variant-drug combination with moderate evidence of an association. The association must be replicated but 
there may be some studies that do not show statistical significance, and/or the effect size may be small; Level 3: annotation for a variant-drug combination based on a 
single significant (not yet replicated) or annotation for a variant-drug combination evaluated in multiple studies but lacking clear evidence of an association; Level 4: 
annotation based on a case report, non-significant study or in vitro, molecular or functional assay evidence only
Snp Id
(gene)
Functional
annotation
Level of  
evidence
Druga Minor Major Parameters Risk allele Genotype
(A1A1-A1A2-A2A2)
A
 rs4244285
(CYP2C19)
exonic,
synonymous
4 Doxorubicin,  
cyclophosphamide, 
tamoxifen
A G Efficacy A (FVG freq 
<1000G/
ExAC)
3AA-48AG-265GG
 rs714368
(SLC22A16)
exonic,
nonsynonymous
4 Doxorubicin, doxoru-
bicinol, cyclophos-
phamide
C T Toxicity T (FVG freq 
>1000G/
ExAC)
118CC-618CT-836TT
 rs4880
(SOD2)
exonic,
nonsynonymous
2B/3* Cyclophosphamide/
tamoxifen
A G Efficacy G (FVG freq 
>1000G/
ExAC)
110GG-157GA-49AA
 rs1801274
(FCGR2A)
exonic,
nonsynonymous
2B Trastuzumab,  
doxorubicin,  
paclitaxel, cyclo-
phosphamide
G A Efficacy G (FVG freq 
<1000G/
ExAC)
289GG-741GA-542AA
 rs1136201
(ERBB2)
exonic,
nonsynonymous
3 Trastuzumab G A Toxicity G (FVG freq 
<1000G/
ExAC)
49GG - 437GA - 1095AA
 rs2297595
(DPYD)
exonic,
nonsynonymous
2A Capecitabine,  
fluorouracil
C T Toxicity C (FVG freq 
<1000G/
ExAC)
20CC-247CT-1314TT
 rs3918290
(DPYD)
splicing,
NA
1 Capecitabine,  
fluorouracil
T C Toxicity T (FVG freq 
<1000G/
ExAC)
0TT-2TC-1579CC
 rs1048943
(CYP1A1)
exonic,
nonsynonymous
3 Docetaxel,  
capecitabine
C T Efficacy T (FVG freq 
>1000G/
ExAC)
6CC-189CT-1386TT
 rs776746b
(CYP3A5)
splicing,
NA
3/Not reported Paclitaxel/ 
tamoxifene
T C Toxicity T (FVG freq 
>1000G)
18TT-216TC-1337CC
B
 rs2369049
(TCL1A)
intergenic,
NA
Not reported Exemestane,  
anastrozole
G A Not defined Not defined 18GG-315GA-1247AA
 rs2072671
(CDA)
exonic,
nonsynonymous
Not reported Capecitabine C A Not defined Not defined 255CC-721CA-605AA
 rs180  1159
(DPYD)
exonic,
nonsynonymous
Not reported Capecitabine C T Not defined Not defined 84CC-518CT-979TT
 rs6214
(IGF1)
UTR3,NA Not reported Tamoxifen T C Not defined Not defined 198TT-707TC-666CC
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of this allele in the EUR/ExAC cohorts is 21–22 % while in 
our population is 27 % (p = 6.9E−03) (Table 1). A minor 
effect (p = 5.5E−2) of increased exposure to doxorubicin 
associated with rs714368 C rare allele homozygosity was 
observed in Lal et al. [21]. Conversely, a more recent study 
[19] has associated, a decreased incidence of dose delay 
with the carrying of the C allele, both at the homozygous 
and heterozygous status. Considering that the T allele is 
more frequent in FVG cohorts (Table 2A), there is a higher 
proportion of individuals which may experience higher tox-
icity for doxorubicin (LOE 4).
The rs4880 G allele (located within super superoxide 
dismutase 2-SOD2-gene) has been correlated with lower 
survival in breast cancer patients treated with chemo-
therapy (p  =  1E−3). However, the effect was mostly 
restricted to those treated with cyclophosphamide-based 
adjuvant regimens (p value for cyclophosphamide–geno-
type interaction = 2.3E−2, LOE 2B), an association rep-
licated in two independent cohorts (US and Norwegian 
patients) [22]. More recently, AA genotype has been 
associated with statistically significant better progres-
sion-free and overall survival in patients treated with 
adjuvant tamoxifen [23]. In the EUR/ExAC cohorts the 
frequency of the G allele is 46 and 51 % respectively while 
in FVG population is 54.5  % (p  =  1.9E−02; 7.8E−02) 
suggesting a quite high percentage of at risk genotype in 
FVG region (Table 2A).
The introduction of the anti-HER2 monoclonal antibody 
(mAb) trastuzumab in clinical practice has revolutionized 
the treatment of HER-2 positive breast cancer patients. 
In fact, their mechanism of actions relies on their ability 
to inhibit the target surface molecules and to trigger anti-
body-dependent cellular cytotoxicity (ADCC), a process 
which involve fragment crystallizable (FC) receptors. Based 
on some retrospective studies, it could be speculated that 
polymorphisms of FC receptor resulting in differential FC 
affinity can reduce the activity of those mAb [24].
Regarding rs1801274 (FCGR2A gene), the frequency of 
G allele in our cohort is 42 % while in EUR/ExAC cohorts 
is 49–50  % (p =  1.5E−02; 9.2E−07) (Tables  1 and 2A). 
Exome chip data supports this result. The most frequent 
genotype in FVG cohorts is AG. In trastuzumab treated 
patients, this genotype, as compared to AA genotype, 
was significantly associated with decreased response and 
shorter progression-free survival (LOE 2B) [25, 26]. Nev-
ertheless, these data should be considered with caution. 
In fact, the association between rs1801274 FCGR2A and 
response to trastuzumab in metastatic [25] or neoadju-
vant [26] setting comes from the retrospective analyses 
of small patient cohorts. Conversely, Hurvitz et al. failed 
to reproduce these observations by evaluating more than 
one thousand patients enrolled onto an adjuvant rand-
omized trial [24, 27].
Although trastuzumab is generally well tolerated, its 
use is often associated with a clinically relevant cardio-
toxicity thus a particular caution in the qualification for 
treatment is necessary and the genotype information 
could improve the physician’s decision-making process. 
A recent investigation has shown that protein modifica-
tion induced by rs1136201 ERBB2 polymorphisms may 
render cardiomyocytes dependent upon HER2 signal-
ing and more sensitive to trastuzumab-mediated toxic-
ity [28] (LOE 3). According to this study, patients with 
the AA genotype may have decreased risk of cardiotox-
icity as compared to patients with the AG genotype fol-
lowing trastuzumab administration (p  =  5.8E−3) [28]. 
The frequency of G allele for rs1136201 is 17 % in FVG 
cohorts and between 24 and 25 % in EUR/ExAC cohorts 
(p =  3.6E−5; 2.4E−13), while the frequency of low risk 
AA patients in our cohort is 69 % (Tables 1 and 2A).
Fluoropyrimidine (i.e., capecitabine, 5-fluoruracil) 
are another class of drugs widely used in breast cancer. 
Dihydropyrimidine dehydrogenase (DPD) eliminates 
more than 80 % of the administered drug and is the rate-
limiting enzyme foruoropyrimidine catabolism. Cancer 
patients carrying mutations in the dihydropyrimidine 
dehydrogenase gene (DPYD) have a high risk to develop 
severe drug-adverse effects following fluoropyrimi-
dine drugs administration. These side effects consist in 
myelosuppression, mucositis, neurotoxicity, hand–foot 
syndrome, and diarrhea, which can be life-threatening. 
Guidelines that recommend alternative drugs or different 
dose adjustment according to DPYD genotype have been 
developed [29, 30].
The DPYD rs2297595 C allele encodes for an inactive 
DPYD variant and has been strongly associated with 
fluoropyrimidine-related toxicity [10, 31, 32] (LOE 2A). 
The rs2297595 showed a frequency of C allele of 10–12 % 
in EUR/ExAC cohorts respectively while in our popula-
tion is 7  % (p =  8.3E−3). Data on the extended sample 
size (1581 individuals) confirmed this result (allele C fre-
quency = 9 %; p = 3.3E−02; 5.4E−02) (Tables 1 and 2A).
The rs3918290 is the most well studied DPYD vari-
ant and the T allele variant is associated with increased 
toxicity (LOE 1). This intronic polymorphism results 
in a splicing variant skipping an entire exon and a non-
functional protein [33]). The frequency of T allele was 
extremely low in our population (0.063  % vs 0.6–1  %, 
FGV vs EUR/ExAC populations, respectively, Table 2A).
Homozygous TT genotypes (i.e., those with a severe 
outcome) are not present in our cohort, while there are 
two out of 1581 CT heterozygous individuals (five hete-
rozygous cases out of 379 samples in EUR cohort). A low 
frequency of at risk DPYD rs2297595 C and rs3918290 T 
genotypes might be a good indicator for physicians (see 
Table 2A).
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We also noticed a different distribution of rs1048943 
(CYP1A1 gene) in our vs EUR/ExAC cohort. CYP1A1 
is likely involved in the metabolism of fluoropyrimi-
dine [34]. Metastatic breast cancer patients carrying TT 
genotype may suffer a decreased progression-free sur-
vival when treated with capecitabine plus docetaxel [35] 
(LOE 3). The frequency of C allele in our cohort was 
6.8 % (6.3 % in Exome chip data) and 3–4 % in the EUR/
ExAC cohort (p  =  2.4E−2, 5.7E−18). Although in the 
PharmGKB website is reported an association between 
this variant and taxane, Vaclavikova et  al. indicates that 
CYP1A1 does not metabolize taxanes [36], implying that 
the association noticed is driven by the effect on this pol-
ymorphism on capecitabine.
Finally, we found a different distribution of rs776746 
(CYP3A5) T allele between EUR (8  %) and our popula-
tion (5  %). In this regard, a recent study reported this 
variant as significantly associated with severe neutrope-
nia in breast cancer patients treated with paclitaxel (LOE 
3), another critical drug widely used in both metastatic 
and adjuvant setting [37] (Table 2A). This polymorphism 
has also been studied in the setting of adjuvant tamox-
ifen, but no correlation with recurrence risk of disease 
has been detected [38].
Genetic variants with doubtful role related with breast 
cancer medications
In addition to the above mentioned associations, we 
found 4 variants (rs2369049 close to TCL1A gene, 
rs2072671 within CDA gene; rs1801159 within DPYD 
gene, rs6214 within IGF1 gene) of genes listed as “related” 
to breast cancer medications by PharmGKB having a dif-
ferent distribution between the FGV and EUR/ExAC 
cohorts but for which the LOE of drug-variant asso-
ciation was not reported. By reviewing the pertinent 
literature we found that all but one of these polymor-
phisms (rs2369049-TCL1A), the underlying studies were 
largely negative [39, 40]. As for rs2369049, however, two 
studies detected an association with exemestane toxicity 
but in opposite direction [39, 41].
Aggregated analysis of variants at risk
To further increase our knowledge on combined at risk 
genotypes (i.e., pooling together the genetic data avail-
able regarding) related to each treatment, we divided 
therapeutic agents in six main classes (see “Methods” 
section). The combined presence of the described risk 
alleles (Table 2A) was checked within each class.
For three of those classes, the members (i.e., the breast 
cancer medications) did not share any of the reported 
at risk genotype. We then defined, for the three remain-
ing classes, the proportion of at risk subjects within each 
class by calculating the overall cumulative frequency of 
at risk genotypes (Table 3). The results are described as 
follows.
Fluoropyrimidines (capecitabine and 5-fluorouracil). 
No subjects carried all the three at risk genotypes [e.g., 
rs2297595 (DPYD gene), rs1048943 (CYP1A1 gene), and 
rs3918290 (DPYD gene)]. We observed that only 1.26 % 
of the analyzed samples carried both at risk genotypes 
for rs2297595 and rs1048943 polymorphisms, while the 
0.06 % of subjects carried the rs3918290 and rs1048943 
at risk alleles or the rs3918290 and rs2297595 risk alleles.
Alkylating agents (cyclophosphamide). Approximately 
1 % (1.20 %) of our sample could be at risk of a poor out-
come being a carrier of both at risk genotypes for rs4880 
and rs4244285 variants.
Monoclonal antibodies (i.e., trastuzumab). Approxi-
mately 18  % (18.40  %) of our cohort carried the at risk 
genotypes for both rs1136201 and rs1801274.
Table 3 At risk genotype’s counts by drug/therapy class
Out of six classes, members of three of them (i.e., the breast cancer medications) did not share any of the reported at risk genotype. For class 1, three SNPs related 
with Fluoropyrimidines were found and different combinations are reported. Drug class class of drugs or treatment, At risk genotype risk genotype for the class, At risk 
genotype count count of joint risk genotypes for the class, Samples total number of analyzed samples, Genotype frequency at risk genotype frequency
Class number Drug class At risk genotype At risk genotype  
count
Samples Genotype  
frequency
1 Fluoropyrimidines
 rs2297595 + rs1048943 + rs3918290 CC + CT & TT & TT + CT 0 1581 0
 rs2297595 + rs1048943 CC + CT & TT 20 1581 1.26 %
 rs2297595 + rs3918290 CC + CT & TT + CT 1 1581 0.06 %
 rs1048943 + rs3918290 TT & TT + CT 1 1581 0.06 %
2 Alkylating agents
 rs4880 + rs4244285 GA + GG & AA 4 331 1.20 %
3 Monoclonal antibodies
 rs1136201 + rs1801274 GA & GG + GA 291 1581 18.40 %
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Discussion
In this study, by taking advantage of the participation to 
a Pilot National Project on a specific set of isolated com-
munities of North-Eastern Italy (i.e., FVG population) 
and compared to those from EUR population and ExAC 
database, we described the distribution of polymor-
phisms related to breast cancer medications.
Despite the frequencies of most polymorphisms were 
similar between the EUR, ExAC and the FVG cohort, 
more than 30  % of variants analyzed significantly dif-
fered among these cohorts. A certain LOE was reported 
for 9 out of those 13 variants, while for four of them the 
related literature fails to detect any kind of association 
(LOE not reported).
Variants for which a LOE was available include poly-
morphisms linked to cyclophosphamide, tamoxifen, 
doxorubicin, fluorpyrimidine and paclitaxel. As for cyclo-
phosphamide, one polymorphism (i.e., rs4880-G) within 
the SOD2 gene was associated with poor outcome (LOE 
2B) and showed a higher frequency in the FVG as com-
pared to EUR/ExAC cohort. Another variant, located in 
the CYP2C19 gene (i.e., rs4244285-A), had a lower fre-
quency in our population. Importantly, the rs4880-G has 
also been associated with poor response to tamoxifen 
(LOE 3). Notably, only a small proportion of FVG popu-
lation (i.e., 1.2 %) carried both at risk polymorphisms.
Regarding doxorubicine and paclitaxel, we observed 
that the frequency of two alleles such as rs714368-
T (SLC22A16) and rs776746-C (CYP3A5), associated 
respectively with toxicity to doxorubicine (LOE 4) and 
paclitaxel (LOE 3), displayed a higher frequency in the 
FVG cohort. These findings imply that that those two 
drugs could be less tolerated by FVG patients.
As for trastuzumab, one variant within the FCGR2A 
gene (rs1801274-G), which is associated with decreased 
efficacy (LOE 2B), and one variant within the ERBB2 
gene, which is implicated in cardiomyopathy develop-
ment (LOE 3), were underrepresented in FVG popula-
tion suggesting an higher therapeutic index of this drug 
in our population as compared to that expected in the 
overall European population. Nevertheless, 18.4  % of 
subjects in our cohort carried the at risk genotypes for 
both rs1136201 and rs1801274, thus highlighting that 
a considerable proportion of patients in FVG displays a 
particularly unfavorable genotype despite the frequency 
of such polymorphisms is lower as compared to the one 
observed in the EUR cohort.
As far as fluorpyrimidines is concerned, the frequency 
of two polymorphisms within the DPYD gene associated 
with drug toxicity (e.g., rs2297595 C allele and rs3918290 
T allele, LOE 2A and 1, respectively) was extremely 
low in FVG population. A number of studies have con-
clusively demonstrated that patients with functional 
alteration of DPYD gene can experience life threatening 
adverse events following fluoropyrimidine administra-
tion. The rs3918290 is the most well characterized DPYD 
variant and dosing guidelines have been developed. The 
clinical pharmacogenetics implementation consortium 
(CPIC) for dihydropyrimidine dehydrogenase geno-
type and fluoropyrimidine dosing recommends to select 
alternative drugs in case of homozygosity for rs3918290 
T allele and to reduce dose by 50  % or select alterna-
tive drug in case of heterozygosity [29]. T allele was 
extremely rare in FVG population and homozygous TT 
genotypes (i.e., those ones with a severe outcome) were 
not present in our cohort, while there were only 2 out of 
1581 CT heterozygous individuals. The frequency of the 
rs1048943 T allele (CYP1A1 gene), which has been asso-
ciated with toxicity of capecitabine-containg regimens, 
was higher in FVG population. However, the clinical 
relevance of this association is not clearly defined (LOE 
3). Importantly, only 0.06 % of the FVG patients carried 
both at risk genotypes for rs3918290 and rs1048943 poly-
morphisms and only 1.2 % for rs2297595 and rs1048943 
variants. Overall, considering the clinical relevance of the 
DPYD data, these results suggest that a larger number of 
FVG patients could benefit from full dosage of fluoropy-
rimidine therapy.
As for tamoxifene, several studies have assessed the 
impact of cytochrome CYP2D6 genotype on treat-
ment responsiveness but results are clashing. Although 
CYP2D6 data were not available in our cohort, a recent 
meta-analysis on 25 studies enrolling more than 13 thou-
sand individuals concluded that there is no sufficient evi-
dence to support CYP2D6 genotyping in patients treated 
with tamoxifen [40].
The information derived from our study will be trans-
ferred to the Regional Health Care Network in order to 
prepare specific leaflets to accurately inform local hos-
pitals and physicians allowing the implementation of 
genomic medicine. While we found that one-third of 
the analyzed variants had a different frequency in our vs 
the EUR/ExAC cohort, we also noticed that for most of 
the assessed targets the respective LOE was weak (LOE 
3–4) and further investigations are needed to confirm the 
reported associations. Implementation of such approach 
in breast-cancer clinical setting could fill this knowledge 
gap, which is a necessary step to prospectively refine the 
impact of a patient-based personalized treatment.
Conclusions
In conclusion, our explorative study highlights the 
importance of assessing gene polymorphisms related 
with cancer medications in isolated populations. In 
particular, the finding that specific functional variants, 
strongly associated with toxicity or lack of efficacy, are 
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more prevalent in a specific community could lead to the 
development of regional targeted interventions aimed at 
a direct screening of such risk genes/variants for example 
by using targeted re-sequencing approach. This in turn 
could facilitate a more effective and rationale usage of the 
healthcare economic resources thus paving the way for a 
personalized medicine [42].
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